References
- Surveillance E, and End Results program (SEER). Cancer stat facts: liver and intrahepatic bile duct cancer. https://seer.cancer.gov/statfacts/html/livibd.html
- NCCN Clinical Practice Guidelines in Oncology. Hepatobiliary cancers. Version 3. 2020 – June 1 2020. www.nccn.org/professionals/physician_gls/pdf/hepatobiliary.pdf
- Herbst DA, Reddy KR. Risk factors for hepatocellular carcinoma. Clin. Liver Dis. 1(6), 180–182 (2012).
- Park JW, Chen M, Colombo M et al. Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE study. Liver Int. 35(9), 2155–2166 (2015).
- Yang JD, Gyedu A, Afihene MY et al. Hepatocellular carcinoma occurs at an earlier age in Africans, particularly in association with chronic hepatitis B. Am. J. Gastroenterol. 110(11), 1629–1631 (2015).
- Frager SZ, Schwartz JM. Hepatocellular carcinoma: epidemiology, screening, and assessment of hepatic reserve. Curr Oncol. 27(13), 138–143 (2020).
- Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, Roberts LR. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol. 16(10), 589–604 (2019).
- Scott VL, Wahl KM, Soltys K, Belani KG, Beebe DS, Davis PJ. Chapter 28 – anesthesia for organ transplantation. In: Smith’s Anesthesia for Infants and Children (8th Edition). Cladis FP, Motoyama EK (Eds). Mosby, Philadelphia (2011).889–949
- Bayer HealthCare. NEXAVAR (sorafenib) tablets, for oral use. December 2018. labeling.bayerhealthcare.com/html/products/pi/Nexavar_PI.pdf
- Llovet JM, Ricci S, Mazzaferro V et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359(4), 378–390 (2008).
- Kudo M, Finn RS, Qin S et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet 391(10126), 1163–1173 (2018).
- US Food and Drug Administration. FDA approves lenvatinib for unresectable hepatocellular carcinoma. www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-lenvatinib-unresectable-hepatocellular-carcinoma
- US Food and Drug Administration. FDA approves atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma. www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-atezolizumab-plus-bevacizumab-unresectable-hepatocellular-carcinoma
- Finn RS, Qin S, Ikeda M et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N. Engl. J. Med. 382(20), 1894–1905 (2020).
- US FDA. FDA approves tremelimumab in combination with durvalumab for unresectable hepatocellular carcinoma (2022). www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-tremelimumab-combination-durvalumab-unresectable-hepatocellular-carcinoma
- Abou-Alfa GK, Lau G, Kudo M et al. Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. N. Engl. J. Med. Evid. 1(8), EVIDoa2100070 (2022).
- National Comprehensive Cancer Network ®. NCCN Clinical Practice Guidelines in Oncology: hepatobiliary cancer v5.2022–January 13, 2023. www.nccn.org/guidelines/guidelines-etail?category=1&id=1438
- US FDA. FDA grants accelerated approval to nivolumab for HCC previously treated with sorafenib. www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-nivolumab-hcc-previously-treated-sorafenib
- El-Khoueiry AB, Sangro B, Yau T et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet 389(10088), 2492–2502 (2017).
- US FDA. Regorafenib. www.fda.gov/drugs/resources-information-approved-drugs/regorafenib
- Bruix J, Qin S, Merle P et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 389(10064), 56–66 (2017).
- Zhu AX, Kang YK, Yen CJ et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased ɑ-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 20(2), 282–296 (2019).
- US FDA. FDA approves ramucirumab for hepatocellular carcinoma. www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-ramucirumab-hepatocellular-carcinoma
- Edge SB, Byrd DR, CC C, Fritz A, Greene FL, Trotti A. AJCC Cancer Staging Manual (Seventh Edition). Springer International Publishing: American Joint Committee on Cancer, 672(2010).
- Kok VC, Chen YC, Chen YY et al. Sorafenib with transarterial chemoembolization achieves improved survival vs. sorafenib alone in advanced hepatocellular carcinoma: a nationwide population-based cohort study. Cancers (Basel) 11(7), (2019).
- Marrero JA, Kudo M, Venook AP et al. Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: The GIDEON study. J. Hepatol. 65(6), 1140–1147 (2016).
- Sarpel U, Spivack JH, Berger Y et al. The effect of locoregional therapies in patients with advanced hepatocellular carcinoma treated with sorafenib. HPB 18(5), 411–418 (2016).
- Geschwind JF, Gholam PM, Goldenberg A et al. Use of transarterial chemoembolization (TACE) and sorafenib in patients with unresectable hepatocellular carcinoma: US regional analysis of the GIDEON registry. Liver Cancer 5(1), 37–46 (2016).
- Varghese J, Kedarisetty C, Venkataraman J et al. Combination of TACE and sorafenib improves outcomes in BCLC stages B/C of hepatocellular carcinoma: a single centre experience. Ann. Hepatol. 16(2), 247–254 (2017).
- Apostolidis L, Pfeiffenberger J, Gotthardt D et al. Survival of hepatocellular carcinoma patients treated with sorafenib beyond progression. Gastrointest. Tumors 5(1–2), 38–46 (2018).
- Arizumi T, Ueshima K, Iwanishi M et al. Real-life clinical practice with sorafenib in advanced hepatocellular carcinoma: a single-center experience second analysis. Dig. Dis. 33(6), 728–734 (2015).
- Bonafede MM, Korytowsky B, Singh P et al. Treatment patterns and economic burden by lines of therapy among patients with advanced hepatocellular carcinoma treated with systemic cancer therapy. J Gastrointest Cancer. 51(1), 217–226 (2020).
- Sardinha M, Simão D, Reis A et al. P-87 Real-world data of nivolumab in advanced hepatocellular carcinoma: a multi-centric and retrospective study. Ann. Oncol. 32, (2021).
- Lim HY, Merle P, Finn RS et al. Regorafenib in patients with unresectable hepatocellular carcinoma (uHCC) in routine clinical practice: interim analysis of the prospective, observational REFINE trial. J. Clin. Oncol. 38(4), 542 (2020).
- Granito A, Forgione A, Marinelli S et al. Experience with regorafenib in the treatment of hepatocellular carcinoma. Therap. Adv. Gastroenterol. 14, 17562848211016959 (2021).
- Merle P, Lim HY, Finn RS et al. Sequential treatment with sorafenib (SOR) followed by regorafenib (REG) in patients (pts) with unresectable hepatocellular carcinoma (HCC): interim analysis of the observational REFINE study. J. Clin. Oncol. 38(Suppl. 15), e16680-e (2020).
- Granito A, Marinelli S, Terzi E et al. Metronomic capecitabine as second-line treatment in hepatocellular carcinoma after sorafenib failure. Dig. Liver Dis. 47(6), 518–522 (2015).
- Trevisani F, Brandi G, Garuti F et al. Metronomic capecitabine as second-line treatment for hepatocellular carcinoma after sorafenib discontinuation. J. Cancer Res. Clin. Oncol. 144(2), 403–414 (2018).
- Li X, Wang Y, Ye X, Liang P. Locoregional combined with systemic therapies for advanced hepatocellular carcinoma: an inevitable trend of rapid development. Front. Mol. Biosci. 8, 635243 (2021).
- Wang K, Wang C, Jiang H, Zhang Y, Lin W, Mo J et al. Combination of ablation and immunotherapy for hepatocellular carcinoma: where we are and where to go. Front. Immunol. 12, 792781 (2021).
- EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. Eur. J. Cancer 48(5), 599–641 (2012).
- Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin. Liver Dis. 19(3), 329–338 (1999).
- Cillo U, Vitale A, Grigoletto F et al. Prospective validation of the Barcelona Clinic Liver Cancer staging system. J. Hepatol. 44(4), 723–731 (2006).
- Johnson PJ, Berhane S, Kagebayashi C et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J. Clin. Oncol. 33(6), 550–558 (2015).
- Pinato DJ, Sharma R, Allara E et al. The ALBI grade provides objective hepatic reserve estimation across each BCLC stage of hepatocellular carcinoma. J. Hepatol. 66(2), 338–346 (2017).